Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EBITDA (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed EBITDA for 7 consecutive years, with -$20.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 5.0% to -$20.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$79.8 million, a 16.0% increase, with the full-year FY2025 number at -$74.8 million, down 691.16% from a year prior.
  • EBITDA was -$20.4 million for Q4 2025 at Fulcrum Therapeutics, up from -$21.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$17.0 million in Q1 2021 to a low of -$34.0 million in Q2 2022.
  • A 5-year average of -$23.0 million and a median of -$21.0 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 73.25% in 2022, then surged 34.79% in 2025.
  • Fulcrum Therapeutics' EBITDA stood at -$23.8 million in 2021, then tumbled by 43.09% to -$34.0 million in 2022, then rose by 19.41% to -$27.4 million in 2023, then increased by 29.19% to -$19.4 million in 2024, then dropped by 5.0% to -$20.4 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's EBITDA are -$20.4 million (Q4 2025), -$21.9 million (Q3 2025), and -$19.8 million (Q2 2025).